Cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors are currently in widespread use for the treatment of both advanced metastatic and early-stage hormone receptor (HR)-positive, human epidermal growth factor receptor (HER2)- negative breast cancer. The gene discussed is ERBB2; the disease is breast cancer.